Try our corporate solution for free!
(212) 419-8286
hadley.ward@statista.com

Revenue of top 20 respiratory brands in the U.S. 2016

This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.

Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.

Top 20 respiratory brands in the U.S. based on revenue in 2016

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

$39 $59 per month *
in the first 12 months
33% discount until December 20th
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$468 / Year
$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

April 2017

Region

United States

Survey time period

2016

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on "Chronic Obstructive Pulmonary Disease (COPD) in the U.S. "

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.